H.R.2430: FDA Reauthorization Act of 2017
Author's Summary: "This bill amends the Federal Food, Drug, and Cosmetic Act to extend through FY2022 and revise Food and Drug Administration (FDA) user fees for new drug applications. User fees are eliminated for supplements to new drug applications and drug manufacturing facilities."
According to the American Academy of Pediatrics (AAP): "Children are not just little adults; medical devices and medications work differently in children and must be studied specifically for their use," said AAP President Fernando Stein, MD, FAAP. "While the overall legislation misses critical opportunities to ensure that all drugs used in children are studied in children, the bill does make improvements that will advance appropriate and safe medical devices available for children."